ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs
March 14 2018 - 04:31PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that three posters highlighting the Company’s
expertise in ADCs will be presented at the upcoming American
Association of Cancer Research (AACR) Annual Meeting to be held
from April 14-18, 2018 in Chicago.
“ImmunoGen has in-depth expertise in all aspects of ADCs, which
has resulted in the most comprehensive toolbox of ADC technologies
in the industry,” said Richard Gregory, Ph.D., ImmunoGen’s chief
scientific officer. “The data to be presented at AACR further build
on our leadership position in the space and demonstrate continued
innovation, including further advancements to payloads and targets
for anti-tumor activity, as well as insights into factors that
determine the clinical efficacy of ADCs.”
Details of ImmunoGen’s poster presentations are as follows:
Title: “A new class of DNA alkylating
indolino-benzodiazepine agents (BIAs) linked with a DNA binding
moiety for use with antibody-drug conjugates (ADCs)” (abstract
#747)Date: April 15, 2018Time: 1:00 – 5:00pm CT
- A new class of DNA alkylating effector
molecules for use in ADC development in which an IGN
(indolino-benzodiazepine) monomer subunit is connected to a DNA
binding moiety (e.g., Bi-Aryl, or Bis-Aryl) are termed BIAs. BIA
ADCs displayed potent, antigen-specific in vitro activity across a
panel of FRα-expressing cell lines. In vivo, these ADCs
demonstrated potent efficacy in xenograft models at doses well
below the maximum tolerated dose.
Title: “Development of an in vivo model system to assess
the interplay between the various drivers of antibody drug
conjugate (ADC) activity” (abstract #753)Date: April 15,
2018Time: 1:00 – 5:00pm CT
- To better understand the variables that
impact ADC pharmacokinetics, tolerability, bio-distribution, and
efficacy, a novel, cross-reactive model system was created. An
anti-murine folate receptor alpha (FRα) antibody was generated that
binds to both mouse and human FRα. The model system allows
experiments to be designed in a cross-reactive system to examine
how modifications to the antibody, linker or cytotoxic payload
impact safety, and efficacy.
Title: “Evaluation of endoglin/CD105 as a tumor
vasculature target with antibody drug conjugates” (abstract
#2900)Date: April 16, 2018Time: 1:00 – 5:00pm CT
- Endoglin/CD105 is a well-acknowledged
endothelial cell proliferation marker, which is strongly expressed
in tumor-associated vasculature. It was evaluated as an oncology
target using ADCs of an anti-CD105 antibody with potent
anti-microtubule maytansinoids DM1 and DM4, and the highly potent
IGN DNA-alkylating payload, DGN549. Endoglin targeted huRH105-DM
and huRH105-DGN549 conjugates produced modest anti-tumor activity
and therapeutic indices in rat models.
Additional information and full abstracts can be found at
www.aacr.org.
About ImmunoGen, Inc.ImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics
using its proprietary ADC technology. The Company’s lead product
candidate, mirvetuximab soravtansine, is in the Phase 3 FORWARD I
trial for FRα-positive platinum-resistant ovarian cancer, and is in
the Phase 1b/2 FORWARD II trial in combination regimens for
earlier-stage disease. ImmunoGen has three additional
clinical-stage product candidates, two of which are being developed
in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC
technology is also used in Roche's marketed product, Kadcyla®, and
in programs in development by Amgen, Bayer, Biotest, CytomX,
Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information
about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including risks related to preclinical
and clinical studies, their timings and results. A review of these
risks can be found in ImmunoGen's Annual Report on Form 10-K for
the year ended December 31, 2017 and other reports filed
with the Securities and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180314005853/en/
For InvestorsImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorFor MediaImmunoGen,
Inc.Courtney O’Konek,
781-895-0600courtney.okonek@immunogen.comorFTI Consulting
Inc.Robert Stanislaro,
212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2023 to Mar 2024